Cannabinoid receptor 2 agonist ameliorates mesenteric angiogenesis and portosystemic collaterals in cirrhotic rats

Hepatology

Volumn 56, Issue 1, 2012, Pages 248-258

  Huang, Hui Chun ^a   Wang, Sun Sang ^a,b   Hsin, I Fang ^a   Chang, Ching Chih ^a,c   Lee, Fa Yauh ^a   Lin, Han Chieh ^a   Chuang, Chiao Lin ^a,c   Lee, Jing Yi ^a,b   Hsieh, Hsian Guey ^a   Lee, Shou Dong ^d  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c Divisions of Taipei Veterans General Hospital ^*  (Taiwan)

^d CHENG HSIN GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

1 DEOXY 3 (1,1 DIMETHYLBUTYL) DELTA8 TETRAHYDROCANNABINOL; 2 METHYL 3 (1 NAPHTHOYL) 1 PROPYLINDOLE; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; ARACHIDONYL 2 CHLOROETHYLAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR AGONIST; CANNABINOID 2 RECEPTOR; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; ENDOTHELIAL NITRIC OXIDE SYNTHASE; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY BLOOD FLOW; ARTICLE; BILE DUCT LIGATION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; HEMODYNAMICS; LIVER CIRRHOSIS; NONHUMAN; PORTAL VEIN BLOOD PRESSURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SUPERIOR MESENTERIC ARTERY;

ANALYSIS OF VARIANCE; ANIMALS; ARACHIDONIC ACIDS; COLLATERAL CIRCULATION; COMMON BILE DUCT; DISEASE MODELS, ANIMAL; HEMODYNAMICS; HYPERTENSION, PORTAL; LIGATION; LIVER CIRRHOSIS; MESENTERY; NEOVASCULARIZATION, PATHOLOGIC; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, CANNABINOID, CB2; REFERENCE VALUES; RNA, MESSENGER; SPLANCHNIC CIRCULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84863520977     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.25625     Document Type: Article

References (53)

1. Mejias M, Garcia-Pras E, Tiani C, Miquel R, Bosch J, Fernandez M. Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats. HEPATOLOGY 2009; 49: 1245-1256.
2. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997; 18: 4-25.
3. Fernandez M, Vizzutti F, Garcia-Pagan JC, Rodes J, Bosch J. Anti-VEGF receptor-2 monoclonal antibody prevents portal-systemic collateral vessel formation in portal hypertensive mice. Gastroenterology 2004; 126: 886-894.
4. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990; 346: 561-564.
5. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993; 365: 61-65.
6. Blázquez C, González-Feria L, Alvarez L, Haro A, Casanova ML, Guzmán M. Cannabinoids inhibit the vascular endothelial growth factor pathway in gliomas. Cancer Res 2004; 64: 5617-5623.
7. Blazquez C, Casanova ML, Planas A, Del Pulgar TG, Villanueva C, Fernandez-Acenero MJ, et al. Inhibition of tumor angiogenesis by cannabinoids. FASEB J 2003; 17: 529-531.
8. Sitzmann JV, Bulkley GB, Mitchell MC, Campbell K. Role of prostacyclin in the splanchnic hyperemia contributing to portal hypertension. Ann Surg 1989; 209: 322-327.
9. Theodorakis NG, Wang YN, Wu JM, Maluccio MA, Sitzmann JV, Skill NJ. Role of endothelial nitric oxide synthase in the development of portal hypertension in the carbon tetrachloride-induced liver fibrosis model. Am J Physiol Gastrointest Liver Physiol 2009; 297: G792-G799.
10. Gupta RA, Tejada LV, Tong BJ, Das SK, Morrow JD, Dey SK, et al. Cyclooxygenase-1 is overexpressed and promotes angiogenic growth factor production in ovarian cancer. Cancer Res 2003; 63: 906-911.
11. Klenke FM, Gebhard MM, Ewerbeck V, Abdollahi A, Huber PE, Sckell A. The selective Cox-2 inhibitor celecoxib suppresses angiogenesis and growth of secondary bone tumors: an intravital microscopy study in mice. BMC Cancer 2006; 6: 9.
12. Sumanovski LT, Battegay E, Stumm M, Van Der Kooij M, Sieber CC. Increased angiogenesis in portal hypertensive rats: role of nitric oxide. HEPATOLOGY 1999; 29: 1044-1049.
13. Sieber CC, Sumanovski LT, Stumm M, van der Kooij M, Battegay E. In vivo angiogenesis in normal and portal hypertensive rats: role of basic fibroblast growth factor and nitric oxide. J Hepatol 2001; 34: 644-650.
14. Murohara T, Asahara T, Silver M, Bauters C, Masuda H, Kalka C, et al. Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J Clin Invest 1998; 101: 2567-2578.
15. Bátkai S, Járai Z, Wagner JA, Goparaju SK, Varga K, Liu J, et al. Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis. Nat Med 2001; 7: 827-832.
16. Halvorsen JF, Myking AO. The porto-systemic collateral pattern in the rat. Eur Surg Res 1974; 6: 183-195.
17. Pertwee RG. Pharmacology of cannabinoid receptor ligands. Curr Med Chem 1999; 6: 635-664.
18. Franco D, Gigou M, Szekely AM, Bismuth H. Portal hypertension after bile duct obstruction. Effect of the bile diversion on portal pressure in the rat. Arch Surg 1979; 114: 1064-1067.
19. Cameron GR, Hasan SM. Disturbances of structure and function in the liver as the result of biliary obstruction. J Pathol Bacteriol 1958; 75: 33-49.
20. Kountouras J, Billing BH, Scheuer PJ. Prolonged bile duct ligation obstruction: a new experimental model of cirrhosis in the rat. Br J Exp Pathol 1984; 65: 305-311.
21. ω-nitro-L-arginine ameliorates portal-systemic shunting in poral-hypertensive rats. Gastroenterology 1993; 105: 1464-1470.
22. Mittal MK, Gupta TK, Lee FY, Sieber CC, Groszmann RJ. Nitric oxide modulates hepatic vascular tone in normal rat liver. Am J Physiol 1994; 267: G416-G422.
23. Hamilton RL, Berry MN, Williams MC, Severinghaus EM. A simple and inexpensive membrane "lung" for small organ perfusion. J Lipid Res 1974; 15: 182-186.
24. Gores GJ, Kost LJ, LaRusso NF. The isolated perfused rat liver: conceptual and practical considerations. HEPATOLOGY 1986; 6: 511-517.
25. Chojkier M, Groszmann RJ. Measurement of portal-systemic shunting in the rat by using γ-labeled microspheres. Am J Physiol 1981; 240: G371-G375.
26. Hodeige D, de Pauw M, Eechaute W, Weyne J, Heyndrickx GR. On the validity of blood flow measurement using colored microspheres. Am J Physiol 1999; 276: H1150-H1158.
27. Anderson CR, Ponce AM, Price RJ. Immunohistochemical identification of an extracellular matrix scaffold that microguides capillary sprouting in vivo. J Histochem Cytochem 2004; 52: 1063-1072.
28. Foss AJ, Alexander RA, Jefferies LW, Hungerford JL, Harris AL, Lightman S. Microvessel count predicts survival in uveal melanoma. Cancer Res 1996; 56: 2900-2903.
29. Wagner C, de Wit C, Gerl M, Kurtz A, Höcherl K. Increased expression of cyclooxygenase 2 contributes to aberrant renin production in connexin 40-deficient kidneys. Am J Physiol 2007; 293: R1781-R1786.
30. Mitrirattanakul S, Ramakul N, Guerrero AV, Matsuka Y, Ono T, Iwase H, et al. Site-specific increases in peripheral cannabinoid receptors and their endogenous ligands in a model of neuropathic pain. Pain 2006; 126: 102-114.
31. Van Sickle MD, Duncan M, Kingsley PJ, Mouihate A, Urbani P, Mackie K, et al. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 2005; 310: 329-332.
32. Steinle JJ, Lashbrook BL. Cervical sympathectomy regulates expression of key angiogenic factors in the rat choroid. Exp Eye Res 2006; 83: 16-23.
33. Liu LM, Dubick MA. Hemorrhagic shock-induced vascular hyporeactivity in the rat: relationship to gene expression of nitric oxide synthase, endothelin-1, and select cytokines in corresponding organs. J Surg Res 2005; 125: 128-136.
34. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Ann Biochem 1976; 72: 248-254.
35. Torres E, Gutierrez-Lopez MD, Mayado A, Rubio A, O'shea E, Colado MI. Changes in interleukin-1 signal modulators induced by 3, 4-methylenedioxyme- thamphetamine (MDMA): regulation by CB2 receptors and implications for neurotoxicity. J Neuroinflammation 2011; 8: 53.
36. Tiyerili V, Zimmer S, Jung S, Wassmann K, Naehle CP, Lütjohann D, et al. CB1 receptor inhibition leads to decreased vascular AT1 receptor expression, inhibition of oxidative stress, and improved endothelial function. Basic Res Cardiol 2010; 105: 465-477.
37. Járai Z, Wagner JA, Varga K, Lake KD, Compton DR, Martin BR, et al. Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc Natl Acad Sci U S A 1999; 96: 14136-14141.
38. Kozlowska H, Baranowska M, Schlicker E, Kozlowski M, Laudañski J, Malinowska B. Virodhamine relaxes the human pulmonary artery through the endothelial cannabinoid receptor and indirectly through a COX product. Br J Pharmacol 2008; 155: 1034-1042.
39. Cenni G, Blandina P, Mackie K, Nosi D, Formigli L, Giannoni P, et al. Differential effect of cannabinoid agonists and endocannabinoids on histamine release from distinct regions of the rat brain. Eur J Neurosci 2006; 24: 1633-1644.
40. Viscomi MT, Oddi S, Latini L, Pasquariello N, Florenzano F, Bernardi G, et al. Selective CB2 receptor agonism protects central neurons from remote axotomy-induced apoptosis through the PI3K/Akt pathway. J Neurosci 2009; 29: 4564-4570.
41. Newman PJ, Berndt MC, Gorski J, White GC, 2nd, Lyman S, Paddock C, et al. PECAM-1 (CD31) cloning and relation to adhesion molecules of the immunoglobulin gene superfamily. Science 1990; 247: 1219-1222.
42. Medina J, Arroyo AG, Sanchez-Madrid F, Moreno-Otero R. Angiogenesis in chronic inflammatory liver disease. HEPATOLOGY 2004; 39: 1185-1195.
43. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005; 115: 209-218.
44. Muñoz-Luque J, Ros J, Fernández-Varo G, Tugues S, Morales-Ruiz M, Alvarez CE, et al. Regression of fibrosis after chronic stimulation of cannabinoid CB2 receptor in cirrhotic rats. J Pharmacol Exp Ther 2008; 324: 475-483.
45. Casanova ML, Blazquez C, Martinez-Palacio J, Villanueva C, Fernandez- Acenero MJ, Huffman JW, et al. Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. J Clin Invest 2003; 111: 43-50.
46. Guzman M, Galve-Roperh I, Sanchez C. Ceramide: a new second messenger of cannabinoid action. Trends Pharmacol Sci 2001; 22: 19-22.
47. Galiègue S, Mary S, Marchand J, Dussossoy D, Carrière D, Carayon P, et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 1995; 232: 54-61.
48. Majima M, Hayashi I, Muramatsu M, Katada J, Yamashina S, Katori M. Cyclooxygenase-2 enhances basic fibroblast growth factor-induced angiogenesis through induction of vascular endothelial growth factor in rat sponge implants. Brit J Pharmacol 2000; 130: 641-649.
49. De Filippis D, Russo A, De Stefano D, Maiuri MC, Esposito G, Cinelli MP, et al. Local administration of WIN 55, 212-2 reduces chronic granuloma-associated angiogenesis in rat by inhibiting NF-kappaB activation. J Mol Med (Berl) 2007; 85: 635-645.
50. Lagneux C, Lamontagne D. Involvement of cannabinoids in the cardioprotection induced by lipopolysaccharide. Br J Pharmacol 2001; 132: 793-796.
51. Molina-Holgado F, Pinteaux E, Moore JD, Molina-Holgado E, Guaza C, Gibson RM, et al. Endogenous interleukin-1 receptor antagonist mediates anti-inflammatory and neuroprotective actions of cannabinoids in neurons and glia. J Neurosci 2003; 23: 6470-6474.
52. Iwakiri Y, Groszmann RJ. The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule. HEPATOLOGY 2006; 43: S121-S131.
53. Dunn CW, Horton JW, Megison SM, Vuitch MF. Contribution of portal systemic shunt to Kupffer cell dysfunction in obstructive jaundice. J Surg Res 1991; 50: 234-239.